Business
Change of Adviser
Change of Adviser.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 6531U Shield Therapeutics PLC 01 April 2019 \n\n \nShield Therapeutics plc\n(\"Shield\" or the \"Group\")\n \nChange of Adviser\n \nLondon, UK, 1 April 2019: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces the appointment of Peel Hunt LLP as its Nominated Adviser with immediate effect. Peel Hunt will continue to act as broker to Shield. \n \n \n- Ends -\n \nFor further information please contact:\n \n\n\n\nShield Therapeutics plc\n\n\nwww.shieldtherapeutics.com\n\n\n\n\nCarl Sterritt, Chief Executive Officer\n\n\n+44 (0)20 7186 8500\n\n\n\n\nTim Watts, Chief Financial Officer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNominated Advisor and Broker\n\n\n\n\n\n\n\nPeel Hunt LLP\n\n\n\n\n\n\n\nJames Steel/Dr Christopher Golden\n\n\n+44 (0)20 7418 8900\n\n\n\n\n\n\n\n\n\n\n\n\nFinancial PR & IR Advisor\n\n\n\n\n\n\n\nWalbrook PR\n\n\n+44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Helen Cresswell\n\n\n+44 (0)7980 541 893 / +44 (0)7841 917 679\n\n\n\n \n \nAbout Shield Therapeutics plc\nShield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019. For more information please visit www.shieldtherapeutics.com. \n \n\n\n \nAbout Feraccru®\nFeraccru® is a novel, stable, non-salt based oral treatment for adults with iron deficiency with or without anaemia that has been shown to be an efficacious and well-tolerated therapy in a range of controlled phase 3 trials. Following the recently announced1 positive results of the Phase IIIb AEGIS-H2H study ...